Journal: Cancers

Article Title: Immuno-Transcriptomic Profiling of Blood and Tumor Tissue Identifies Gene Signatures Associated with Immunotherapy Response in Metastatic Bladder Cancer

doi: 10.3390/cancers16020433

Figure Lengend Snippet: Mouse model of anti-PD-1-resistant MIBC. ( A ) Survival curves of control MIBC mice treated with isotype control Ab (IsoCT, black, n = 14) and mice treated with either anti-PD-1 (red, n = 9) or anti-PD-1 + anti-CD40 (green, n = 30). **** p < 0.001 by log-rank test. ( B ) Bladder weight 9 days post-treatment for the indicated conditions. Each dot represents the bladder from one mouse (2 pooled experiments).

Article Snippet: One i.p. injection of anti-CD40 (100 μg/dose, FGK45 clone, BioXcell) or IsoCT (100 μg/dose, 2A3 clone, BioXcell) was performed at the beginning of the treatment.

Techniques: Control

Journal: Cancers

Article Title: Immuno-Transcriptomic Profiling of Blood and Tumor Tissue Identifies Gene Signatures Associated with Immunotherapy Response in Metastatic Bladder Cancer

doi: 10.3390/cancers16020433

Figure Lengend Snippet: CD8+ T cells are the major contributors to the gene signatures found in blood after immunotherapy. ( A ) Relative proportion of all immune cells (CD45+) with mean percentage ± SD of the indicated population of lymphocytes in the bladder and the blood. ( B ) Representative FACS histograms and percentages of the indicated markers for the indicated lymphocyte populations. ( C ) Concentration (pg/mL) of CCL5 in the serum of mice. Mice were treated at MIBC stage with either anti-PD-1 and isoCT isotype control (grey, n = 7) or anti-PD-1 and anti-CD40 (orange, n = 7). Analyses were performed 9 days after the beginning of the treatments. For scatter plots, each dot represents an individual mouse, and bars represent the mean. * p < 0.05; ** p < 0.01; *** p < 0.005, **** p < 0.0001 by ANOVA test, followed by a Sidak test.

Article Snippet: One i.p. injection of anti-CD40 (100 μg/dose, FGK45 clone, BioXcell) or IsoCT (100 μg/dose, 2A3 clone, BioXcell) was performed at the beginning of the treatment.

Techniques: Concentration Assay, Control